Skip to main content

Table 2 Comparison between ASV-adherence sub-groups (≤4 h versus > 4 h) for clinical, ASV and monitoring data

From: What is the remaining status of adaptive servo-ventilation? The results of a real-life multicenter study (OTRLASV-study)

 

N

≤4 h

N = 23

> 4 h

N = 154

P

Age (years)

177

74.00 [60.00;82.00]

71.00 [65.00;77.00]

0.964

Gender, n (%)

177

  

0.316

 Female

22

1 (4.35%)

21 (13.64%)

 

 Male

155

22 (95.65%)

133 (86.36%)

 

BMI (kg/m2)

175

29.40 [26.30;32.30)

30.10 [26.95;34.40]

0.379

SA sub-groups, n (%)

177

  

< 0.001

 CSA

105

6 (26.09%)

99 (64.29%)

 

 OSA

36

6 (26.09%)

30 (19.48%)

 

 TESA

36

11 (47.83%)

25 (16.23%)

 

Initial exam, n (%)

177

  

0.692

 PG

101

14 (60.87%)

87 (56.49%)

 

 PSG

76

9 (39.13%)

67 (43.51%)

 

Initial AHI (n/h)

177

50.00 [40.00;67.20]

50.00 [38.00;60.30]

0.636

Final AHIflow

177

2.00 [0.80;5.20]

1.85 [0.70;3.60]

0.362

Initial ESS score

136

12.50 [9.00;16.00]

9.00 [5.00;13.00]

0.012

Final ESS score

174

8.50 [4.00;12.00]

5.00 [3.00;9.00]

0.034

Initial ESS-final ESS score

136

2 (0.00–6.00)

2.50 (0.00–7.00)

0.775

ASV initiation during continuous hospitalization, n (%)

173

13 (61.90%)

65 (42.76%)

0.098

CPAP trial before ASV initiation, n (%)

166

16 (69.57%)

75 (52.45%)

0.126

Interface Type, n (%)

175

   

 Facial

87

12 (52.17%)

75 (49.34%)

0.800

 Nasal/Nasal Pillows

88

11 (47.83%)

77 (50.66%)

 

Cardiological comorbidity/etiology, n (%)

177

18 (78.26%)

116 (75.32%)

0.759

Neurological comorbidity/etiology, n (%)

177

0 (0.00%)

22 (14.29%)

0.053

Renal comorbidity/etiology, n (%)

177

2 (8.70%)

6 (3.90%)

0.278

Opiod comorbidity/etiology, n (%)

177

0 (0.00%)

6 (3.90)

0.336

Idiopathic CSA, n (%)

177

2 (8.70%)

15 (9.74%)

1.000

No comorbidity/etiology, n (%)

177

5 (21.74%)

28 (18.18%)

0.774

Patients with at least one hospitalization for cardiologic cause, n (%)

177

3 (13.04%)

8 (5.19%)

0.157

Number of cardiological medications

169

3.00 [1.00;4.00]

2.00 [1.00;3.00]

0.535

Knowledge of the medical treatment by the patient, n (%)

162

8 (40.00%)

83 (58.45%)

0.119

Echocardiography or cardiological consultation in the last 6 months, n (%)

144

11 (64.71%)

65 (51.18%)

0.294

Oxymetry or Polygraphy ASV control in the last 6 months

157

2 (10.00%)

52 (37.96%)

0.014

Modification of ASV settings as a consequence of Polygraphy or oximetry, n (%)

54

0 (0%)

14 (26.92%)

1.000

  1. Quantitative variables were described by medians and [IQ25–75]
  2. AHI Apnea hypopnea index, AHIflow Apnea Hypopnea Index estimated by the device, BMI Body mass index, CPAP Continuous positive airway pressure, CSA Central sleep apnea, ESS Epworth sleepiness scale, n Number, OSA Obstructive sleep apnea, PG Polygraphy, PSG Polysomnography, TECSA Treatment emergent central sleep apnea, SA Sleep apnea